Targin Forðatafla 10 mg /5 mg איסלנד - איסלנדית - LYFJASTOFNUN (Icelandic Medicines Agency)

targin forðatafla 10 mg /5 mg

mundipharma a/s - oxycodonum hýdróklóríð; naloxonum hýdróklóríð - forðatafla - 10 mg /5 mg

Targin Forðatafla 20 mg /10 mg איסלנד - איסלנדית - LYFJASTOFNUN (Icelandic Medicines Agency)

targin forðatafla 20 mg /10 mg

mundipharma a/s - oxycodonum hýdróklóríð; naloxonum hýdróklóríð - forðatafla - 20 mg /10 mg

Targin Forðatafla 40 mg/20 mg איסלנד - איסלנדית - LYFJASTOFNUN (Icelandic Medicines Agency)

targin forðatafla 40 mg/20 mg

mundipharma a/s - oxycodonum hýdróklóríð; naloxonum hýdróklóríð - forðatafla - 40 mg/20 mg

Targin Forðatafla 5 mg/2,5 mg איסלנד - איסלנדית - LYFJASTOFNUN (Icelandic Medicines Agency)

targin forðatafla 5 mg/2,5 mg

mundipharma a/s - oxycodonum hýdróklóríð; naloxonum hýdróklóríð - forðatafla - 5 mg/2,5 mg

Brukinsa האיחוד האירופי - איסלנדית - EMA (European Medicines Agency)

brukinsa

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - Æxlishemjandi lyf - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).